TruScreen Executive Leadership Change

NZX Announcement
26 February 2021


TRUSCREEN EXECUTIVE LEADERSHIP CHANGE
• Termination of Ms. Victoria Potarina as Chief Executive Officer
• Appointment of current director Ms. Juliet Hull as Interim Chief Executive
Officer

TruScreen Group Limited (the Company) advises that, the Executive Service Agreement
with Ms. Victoria Potarina, Chief Executive Officer of the Company, was terminated with
immediate effect.
Ms. Juliet Hull, a Non-Executive Director of the Company will assume an executive role
as Interim Chief Executive Officer. Juliet holds a MBA from Macquarie Graduate School
of Management and was previously the General Manager and Country Director of
Johnson & Johnson New Zealand. Her extensive leadership experience included working
within the healthcare sectors in Australia and New Zealand with distributors and public
health systems across Greater Asia and Pacific.
“On behalf of the Board, I thank Victoria for her contribution to the company. Over the past
year TruScreen has strengthened its technology and service delivery team. With our
existing teams, and under the guidance of Juliet, we remain well-positioned to continue
our focus on growing sales in our core market of China and continue to supplement this
with our expansion into the developing markets of Mexico, Vietnam, Middle East, Russia,
and Central Eastern Europe,” said Tony Ho, Chairman of Truscreen.
The Company will commence a recruitment process for a new Chief Executive to lead the
Company through its next phase of development.
This release to NZX/ASX has been authorised by the Board.

For more information visit www.TruScreen.com or contact:

TruScreen
Tony Ho
Chairman
tonyho@truscreen.com

TruScreen
Juliet Hull
CEO
juliethull@truscreen.com
Investor Relations
Trevor Chappell

Tchappel@we-worldwide.com

-ENDS-

About TruScreen:
TruScreen cervical cancer screening device offers the latest technology in cervical screening, providing real-
time, accurate detection of precancerous and cancerous cervical cells to help improve the health and well-being
of women around the world.
TruScreen’s real-time cervical cancer technology utilises a digital wand which is placed on the surface of the
cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary
algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by
optical and electrical measurement of cervical tissue.
TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with
conventional Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for
supporting laboratory infrastructure. As such, TruScreen’s target market is low and middle-income countries
where no large-scale cervical cancer screening programs and infrastructure are in place, such as China, Mexico,
Africa, Russia and India. TruScreen’s cervical cancer screening device is CE-marked and certified for use
throughout Europe and CFDA approved for sale in China. The global market potential for TruScreen is
significant.